University of Ioannina
Σπινθηρογραφική μελέτη αιμάτωσης ήπατος και κεντρικού αγγειακού διαμερίσματος αιμοδυναμικά σταθερών κιρρωτικών ασθενών με πυλαία υπέρταση σε συνθήκες ηρεμίας και υπό την επίδραση φαρμάκων χορηγούμενων σε κιρσορραγία
Abstract
dc:descriptionBackground: In liver cirrhosis with portal hypertension, esophagogastric variceal hemorrhage may cause hepatic ischemia and deteriorate the cirrhotic hyperdynamic circulatory state. Therefore, the effect of administered vasoconstrictive medications on the hepatic and central (cardiothoracic) vascular blood reservoirs is of clinical significance. Purpose: This study was conducted in hemodynamically stable patients with liver cirrhosis and portal hypertension with esophagogastric varices. They underwent blood pool scintigraphy by labelled erythrocytes (99mTc-RBC) to evaluate hepatic blood activity (HeBA) and central blood activity (CeBA) and their differences between various clinical stages of cirrhosis, and also compared the effects of two major vasoconstrictor drugs, somatostatin and terlipressin, on HeBA and CeBA. Method: Twenty cirrhotic patients (Child–Pugh stage A/B/C: 5/7/8) with portal hypertension and esophagogastric varices were enrolled. Within 4 days they were submitted in two dynamic scintigraphic examinations, 40 minutes each. The first (baseline) scan was without any intervention, whereas the second (interventional) was conducted after intravenous administration of somatostatin (250 mg bolus, followed by continuous infusion of 250 mg/hr; N=10) or terlipressin (2 mg bolus; N=10). HeBA and CeBA, respective indicators of hepatic perfusion and cardiothoracic blood pool, were estimated at 6 typical time points of the exam: 1st, 5th, 10th, 20th, 30th and 40th minute. On the baseline scan (day 1), HeBA and CeBA were compared between Child–Pugh A, B and C groups. In the interventional exam (day 4), each group were compared with their corresponding baseline HeBA/CeBA values; furthermore, each group’s HeBA/CeBA change –relative to the baseline study– was compared against the other group. Finally, a series of systemic hemodynamic parameters (heart rate, mean arterial pressure [MAP], cardiac output [CO] and systemic vascular resistance [SVR]) were measured twice in the day of the interventional exam; before somatostatin/terlipressin administration and again at the end of the scan. Linear regression analysis was conducted between drug-induced change in the SVR and the HeBA/CeBA change –in relation to the baseline test–. Results: Both HeBA and CeBA are significantly reduced as cirrhosis deteriorates; HeBA mainly between stages B & C, while CeBA between both B & C and A & B. As compared to baseline, somatostatin caused a downward trend of HeBA and non-remarkable change in CeBA (both non-significant), while terlipressin induced a marginal upward trend of HeBA (non-significant) and an increase in CeBA that became statistically significant after the 20th minute of the exam. With regards to HeBa, the comparison between its decrease in the somatostatin group and its incremental trend in the terlipressin group reached statistically significant levels from the 20th minute until the end (40th minute) of the test. The same happened also for CeBA, for which the difference between the two groups reached significant levels from the 30th minute onwards. Hemodynamically, terlipressin significantly reduced heart rate and CO and significantly increased MAP and SVR, whereas somatostatin reduced MAP to a marginally significant level. There was a significant positive correlation between SVR increase under terlipipressin and the increase that this drug induced to CeBA. Conclusion: Hepatic blood volume (as expressed by HeBA) is reduced in proportion to the cirrhosis severity and the central blood volume (reflected by CeBA) decreases accordingly, as cirrhosis progresses to non-decompensated stages. Somatostatin tends to reduce hepatic perfusion, while it does not significantly affect the central blood volume. On the other hand, terlipressin appears to have a positive effect on hepatic blood flow, thus improving hepatic microcirculation and perfusion, while it predominantly enhances the cardiothoracic blood reservoir by increasing the central blood volume and improving the hyperdynamic state of cirrhotic circulation. These effects may be beneficial when this drug is administered for the treatment of acute variceal bleeding, especially in patients with advanced liver disease and severely compromised hepatic perfusion at increased risk of ischemic hepatitis.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsiouris, Spyridon
- Τσιούρης, Σπυρίδων
Subjects
dc:subject × 24- Κίρρωση ήπατος
- Πυλαία υπέρταση
- Σπινθηρογράφημα
- Ραδιοεπισημασμένα ερυθροκύτταρα
- Ηπατική αιματική δεξαμενή
- Καρδιοθωρακική αιματική δεξαμενή
- Αγγειοδραστικά φάρμακα
- Σωματοστατίνη
- Τερλιπρεσσίνη
- Liver cirrhosis
- Portal hypertension
- SCINTIGRAPHY
- Radiolabeled erythrocytes
- Hepatic blood pool
- Cardiothoracic blood pool
- Vasoactive drugs
- Somatostatin
- Terlipressin
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Clinical Medicine
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47461